CONCERTA® (methylphenidate HCI) Extended-Release Tablets CII
(methylphenidate HCI) Extended-Release Tablets CII
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-Release Tablets CII
DITROPAN XL® (oxybutynin chloride)
DITROPAN XL®
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVEGA TRINZA™ (paliperidone palmitate) extended-release injectable suspension 273 mg, 410 mg, 546 mg, or 819 mg
INVEGA TRINZA™
INVOKAMET® (canagliflozin/metformin HCl) tablets
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
OLYSIO® (simeprevir)
ONETOUCH® Meters and Test Strips
ORTHO TRI-CYCLEN® LO (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® LO
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PREZCOBIX™ (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) Tablets
PROCRIT® (epoetin alfa)
RAZADYNE® (galantamine)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab) for infusion
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT® (siltuximab)
TERAZOL® (terconazole)
TOPAMAX® (topiramate) Tablets
ULTRACET® (tramadol hydrochloride/acetaminophen)
ULTRAM® (tramadol hydrochloride)
ULTRAM® ER (tramadol HCI) Extended-Release Tablets
ULTRAM® ER
XARELTO® (rivaroxaban)
ZYTIGA® (abiraterone acetate)

Need help paying for your CONCERTA® (methylphenidate HCI) Extended-Release Tablets CII prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for CONCERTA®. We have also listed most of the eligibility requirements for each so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their web sites to learn more.

To view programs that are best suited for you, select your insurance status for CONCERTA® or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for CONCERTA® or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to medicines for uninsured patients who lack the financial resources to pay for them. If you need CONCERTA® (methylphenidate HCI) Extended-Release Tablets CII, and are uninsured and unable to pay for your medicine, please contact a JJPAF program specialist at 1-800-652-6227 9 AM to 6 PM ET or visit the foundation website at JJPAF.org to see if you might qualify for assistance.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and co-insurance. Find out if your state has a program that can help you.

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription co-insurance and co-payments
  • Have no gap in coverage
March 13, 2015
Expand
Expand

IMPORTANT SAFETY INFORMATION

INDICATION

CONCERTA® is a prescription product approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs. Keep CONCERTA® in a safe place to prevent misuse and abuse.

CONCERTA® should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA®; significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under 6 years of age should not take CONCERTA®.

Tell your healthcare professional if you or your child has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Tell your doctor if you have or your child has numbness, pain, skin color change or sensitivity to temperature in fingers or toes. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA®. Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop priapism, seek medical help right away. Because of the potential for lasting damage, priapism should be evaluated by a doctor immediately. Your child's healthcare professional should check height and weight often and may interrupt CONCERTA® treatment if your child is not growing or gaining weight as expected.

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA® does not adversely affect your ability to engage in such activities.

The most common adverse reaction in double-blind clinical trials (>5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions in double-blind clinical trials (>5%) in adult patients were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis.

CONCERTA® and OROS® are registered trademarks of ALZA Corporation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please see full Product Information for more details.

IMPORTANT SAFETY INFORMATION

INDICATION

CONCERTA® is a prescription product approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs. Keep CONCERTA® in a safe place to prevent misuse and abuse.

CONCERTA® should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA®; significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under 6 years of age should not take CONCERTA®.

Tell your healthcare professional if you or your child has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Tell your doctor if you have or your child has numbness, pain, skin color change or sensitivity to temperature in fingers or toes. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA®. Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop priapism, seek medical help right away. Because of the potential for lasting damage, priapism should be evaluated by a doctor immediately. Your child's healthcare professional should check height and weight often and may interrupt CONCERTA® treatment if your child is not growing or gaining weight as expected.

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA® does not adversely affect your ability to engage in such activities.

The most common adverse reaction in double-blind clinical trials (>5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions in double-blind clinical trials (>5%) in adult patients were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis.

CONCERTA® and OROS® are registered trademarks of ALZA Corporation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please see full Product Information for more details.